Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 2/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.52 |
| ▸ | PLAU | P00749 | 3/20 | 0.51 |
| ▸ | PLG | P00747 | 2/20 | 0.51 |
| ▸ | PLAT | P00750 | 2/20 | 0.51 |
| ▸ | RXRA | P19793 | 3/20 | 0.50 |
| ▸ | RXRB | P28702 | 2/20 | 0.50 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6485280 | 1.00 | HSD17B2 (0.54) | HSD17B2TRPV1PLAUPLGPLAT | |
| SCHEMBL6487507 | 0.85 | MAPT (0.53) | RXRARXRBLTB4R | |
| SCHEMBL28428039 | 0.83 | CES2 (0.61) | KMT2AMEN1 | |
| SCHEMBL4008578 | 0.83 | CES2 (0.61) | KMT2AMEN1 | |
| SCHEMBL4008579 | 0.83 | CES2 (0.61) | KMT2AMEN1 | |
| SCHEMBL2998997 | 0.82 | PLAU (0.58) | HSD17B2TRPV1PLAUPLGPLAT | |
| SCHEMBL505652 | 0.82 | RXRA (0.72) | HSD17B2TRPV1PLAUPLGPLAT | |
| SCHEMBL30837207 | 0.82 | PLAU (0.58) | HSD17B2TRPV1PLAUPLGPLAT | |
| SCHEMBL30278441 | 0.82 | RXRA (0.72) | HSD17B2TRPV1PLAUPLGPLAT | |
| SCHEMBL11243242 | 0.81 | SMN1; SMN2 (0.61) | RXRARXRBLTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867218-B2 | Compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2005-03-15 | — | — | US | disclosed |
| US-20030195200-A1 | Compounds, their preparation and use | VTVX HOLDINGS II LLC | 2003-10-16 | — | — | US | disclosed |
| US-6555577-B1 | For treatment and/or prevention of conditions mediated by the Peroxisome Proliferator-Activated Receptors (PPAR), such as diabetes and/or obesity; 3-(4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl)-2-butoxy-propionic acid for example | NOVO NORDISK A/S (DE) | 2003-04-29 | — | — | US | disclosed |
| EP-1254101-A1 | PROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | Novo Nordisk A/S (DK) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001055085-A1 | PROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | NOVO NORDISK A/S (DK) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195200-A1 | Compounds, their preparation and use | PPARG, PPARA, PPARD | HSD17B2 144/4885TRPV1 946/4885PLAU 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.